更便宜并不总是更好:美国的药物短缺和基于价值的解决方案来缓解它们
Inmaculada Hernandez1, Sean D Sullivan2, Ryan N Hansen2
1Skaggs School of Pharmacy, University of California San Diego.
Journal of managed care & specialty pharmacy
|July 1, 2024
概括
药品短缺,特别是仿制药,源于由于定价做法导致的低利能力. 基于价值的补偿可以激励制造商建立弹性供应链,减少短缺.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 供应链管理 供应链管理
背景情况:
- 药物短缺对患者护理构成重大风险,增加不良健康结果和医疗保健成本.
- 仿制药,特别是注射药,由于利性有限,因短缺而受到不成比例的影响.
- 目前的仿制药补偿和采购做法造成了强烈的价格压力,减少了制造商对供应链弹性的激励.
研究的目的:
- 分析当前市场动态如何导致药物短缺.
- 提出基于价值的报销模式,以激励供应链的弹性和缓解药物短缺.
- 建议在医疗保险中实施这种模式.
主要方法:
- 对当前的退款和购买实践进行了前景分析.
- 基于价值的偿还模式的概念开发.
- 建议整合到补偿的供应链弹性评级系统.
主要成果:
- 目前的做法鼓励成本削减,而不是供应链的稳定性,导致短缺.
- 基于价值的报销系统可以使金融激励与供应链可靠性保持一致.
- 对于弹性供应链的更高补偿金鼓励制造商投资于稳定性.
结论:
- 基于价值的补偿提供了一种政策解决方案,以解决仿制药短缺的根本原因.
- 对供应链弹性进行评级系统对于实施基于价值的报销至关重要.
- 针对初步实施的医疗保险可以利用现有的政策改革努力.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
717
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
717
Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
Bioequivalence: Overview
983
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
983
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Control Governance: Regulatory Bodies and Their Impact
150
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
150


